Overdose Prevention Intervention for Drug Overdose
(Oasis Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).
Do I need to stop taking my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications.
Is naloxone safe for use in preventing opioid overdose?
How is this drug different from other overdose prevention drugs?
What data supports the effectiveness of this drug for overdose prevention?
Research shows that naloxone, a drug used to reverse opioid overdoses, can reduce overdose deaths when prescribed by HIV clinicians. Additionally, buprenorphine, a medication for opioid use disorder, is effective in reducing opioid cravings and overdoses, especially when integrated into HIV care.910111213
Who Is on the Research Team?
Carl Latkin, PhD
Principal Investigator
Johns Hopkins Bloomberg School of Public Health
Are You a Good Fit for This Trial?
This trial is for current opioid users who have used within the last two weeks. It's aimed at people who inject drugs and are at risk of HIV, hepatitis C, or drug overdose. Participants must be able to engage in the study without mental or physical health issues interfering.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive peer education and risk reduction materials in semi-public injection settings
Follow-up
Participants are monitored for changes in overdose and HIV/HCV prevention behaviors
What Are the Treatments Tested in This Trial?
Interventions
- HIV, HCV and overdose prevention
HIV, HCV and overdose prevention is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins Bloomberg School of Public Health
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator